Briefing From The Editor -- TEVA Stock

Large-cap Health Care company Teva Pharmaceutical Industries has moved 2.9% so far today on a volume of 10,479,539, compared to its average of 9,613,223. In contrast, the S&P 500 index moved 0.0%.

Teva Pharmaceutical Industries trades -6.27% away from its average analyst target price of $18.5 per share. The 8 analysts following the stock have set target prices ranging from $9.0 to $22.0, and on average have given Teva Pharmaceutical Industries a rating of buy.

Anyone interested in buying TEVA should be aware of the facts below:

  • Teva Pharmaceutical Industries has moved 123.8% over the last year, and the S&P 500 logged a change of 22.7%

  • Based on its trailing earnings per share of -0.42, Teva Pharmaceutical Industries has a trailing 12 month Price to Earnings (P/E) ratio of -41.3 while the S&P 500 average is 27.65

  • TEVA has a forward P/E ratio of 6.4 based on its forward 12 month price to earnings (EPS) of $2.73 per share

  • The company has a price to earnings growth (PEG) ratio of 4.46 — a number near or below 1 signifying that Teva Pharmaceutical Industries is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 2.7 compared to its sector average of 3.61

  • Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

  • Based in Tel Aviv, the company has 35,001 full time employees and a market cap of $19.64 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.